Sweden
· Delayed Price · Currency is SEK Hansa Biopharma AB Statistics
Total Valuation
Hansa Biopharma AB has a market cap or net worth of SEK 2.72 billion. The enterprise value is 2.99 billion.
| Market Cap | 2.72B |
| Enterprise Value | 2.99B |
Important Dates
The next estimated earnings date is Thursday, October 24, 2024.
| Earnings Date | Oct 24, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Hansa Biopharma AB has 67.81 million shares outstanding. The number of shares has increased by 12.91% in one year.
| Shares Outstanding | 67.81M |
| Shares Change (YoY) | +12.91% |
| Shares Change (QoQ) | +19.48% |
| Owned by Insiders (%) | 7.88% |
| Owned by Institutions (%) | 16.74% |
| Float | 38.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.53 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.73 |
| EV / Sales | 18.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.02 |
Financial Position
The company has a current ratio of 3.05
| Current Ratio | 3.05 |
| Quick Ratio | 3.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.31 |
| Interest Coverage | -4.99 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -37.86% |
| Return on Capital (ROIC) | -50.21% |
| Revenue Per Employee | 1.12M |
| Profits Per Employee | -5.49M |
| Employee Count | 168 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 40.48 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.09% in the last 52 weeks. The beta is 1.44, so Hansa Biopharma AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | +21.09% |
| 50-Day Moving Average | 43.29 |
| 200-Day Moving Average | 37.74 |
| Relative Strength Index (RSI) | 40.57 |
| Average Volume (20 Days) | 108,890 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hansa Biopharma AB had revenue of SEK 163.56 million and -801.64 million in losses. Loss per share was -14.52.
| Revenue | 163.56M |
| Gross Profit | 70.10M |
| Operating Income | -724.47M |
| Pretax Income | -801.13M |
| Net Income | -801.64M |
| EBITDA | -721.44M |
| EBIT | -724.47M |
| Loss Per Share | -14.52 |
Balance Sheet
The company has 705.00 million in cash and 974.48 million in debt, giving a net cash position of -269.48 million or -3.97 per share.
| Cash & Cash Equivalents | 705.00M |
| Total Debt | 974.48M |
| Net Cash | -269.48M |
| Net Cash Per Share | -3.97 |
| Equity (Book Value) | -218.79M |
| Book Value Per Share | -3.23 |
| Working Capital | 564.72M |
Cash Flow
In the last 12 months, operating cash flow was -744.10 million and capital expenditures 289,000, giving a free cash flow of -743.81 million.
| Operating Cash Flow | -744.10M |
| Capital Expenditures | 289,000 |
| Free Cash Flow | -743.81M |
| FCF Per Share | -10.97 |
Margins
| Gross Margin | 42.86% |
| Operating Margin | -442.93% |
| Pretax Margin | -489.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -454.75% |
Dividends & Yields
Hansa Biopharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.91% |
| Shareholder Yield | -12.91% |
| Earnings Yield | -36.22% |
| FCF Yield | -27.37% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |